A review on golimumab in the treatment of psoriatic arthritis
File(s)
Accepted version
Author(s)
Urdaneta, M
Jethwa, H
Sultan, R
Abraham, S
Type
Journal Article
Abstract
Psoriatic arthritis (PsA) causes inflammation in and around the joints and usually affects people who already have psoriasis. However, some patients develop the joint problems before the psoriasis. Currently, there are five anti-TNF-α agents licensed for use in patients with PsA: adalimumab, certolizumab pegol, etanercept, golimumab and infliximab. Golimumab, a human monoclonal antibody, has been approved by the US FDA for the treatment of PsA and is targeted against the pro-inflammatory molecule TNF-α. The Phase III GO-REVEAL study confirmed this drug was well tolerated and showed significant improvement in disease activity compared with placebo.
Date Issued
2017-08-25
Date Acceptance
2017-08-03
Citation
Immunotherapy, 2017, 9 (11), pp.871-888
ISSN
1750-743X
Publisher
Future Medicine
Start Page
871
End Page
888
Journal / Book Title
Immunotherapy
Volume
9
Issue
11
Copyright Statement
© 2017 Future Medicine Ltd
Subjects
Science & Technology
Life Sciences & Biomedicine
Immunology
anti-TNF-alpha
golimumab
inflammation
monoclonal antibody
psoriatic arthritis
Simponi (R)
NECROSIS-FACTOR-ALPHA
PLACEBO-CONTROLLED TRIAL
HUMAN MONOCLONAL-ANTIBODY
LONG-TERM EXTENSION
EVERY 4 WEEKS
RHEUMATOID-ARTHRITIS
ANKYLOSING-SPONDYLITIS
SUBCUTANEOUS GOLIMUMAB
CLINICAL-EFFICACY
OPEN-LABEL
Publication Status
Published